Drug Search Results
More Filters [+]

Cloxacillin

Alternative Names: cloxacillin, cloxapen, tegopen
Latest Update: 2024-12-10
Latest Update Note: Clinical Trial Update

Product Description

Cloxacillin is a semisynthetic beta-lactamase resistant penicillin antibiotic with antibacterial activity. Cloxacillin binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall, thereby preventing the cross-linkage of peptidoglycans, which are critical components of the bacterial cell wall. This leads to an interruption of the bacterial cell wall and causes bacterial cell lysis. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cloxacillin)

Mechanisms of Action: PBP Antagonist,Cell Wall Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Bangladesh | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Denmark | Dominican Republic | Egypt | Finland | France | Germany | Greece | Hong Kong | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Malaysia | Mexico | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Singapore | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | United Arab Emirates | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cloxacillin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events